HK78897A - Antiviral combinations containing nucleoside analogs - Google Patents

Antiviral combinations containing nucleoside analogs

Info

Publication number
HK78897A
HK78897A HK78897A HK78897A HK78897A HK 78897 A HK78897 A HK 78897A HK 78897 A HK78897 A HK 78897A HK 78897 A HK78897 A HK 78897A HK 78897 A HK78897 A HK 78897A
Authority
HK
Hong Kong
Prior art keywords
nucleoside analogs
combinations containing
containing nucleoside
antiviral combinations
antiviral
Prior art date
Application number
HK78897A
Other languages
English (en)
Inventor
Janet Mary Cameron
Nicholas Cammack
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK78897(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919110624A external-priority patent/GB9110624D0/en
Priority claimed from GB919121381A external-priority patent/GB9121381D0/en
Priority claimed from GB919123581A external-priority patent/GB9123581D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK78897A publication Critical patent/HK78897A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK78897A 1991-05-16 1997-06-12 Antiviral combinations containing nucleoside analogs HK78897A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919110624A GB9110624D0 (en) 1991-05-16 1991-05-16 Combinations
GB919121381A GB9121381D0 (en) 1991-10-08 1991-10-08 Combinations
GB919123581A GB9123581D0 (en) 1991-11-06 1991-11-06 Combinations

Publications (1)

Publication Number Publication Date
HK78897A true HK78897A (en) 1997-06-20

Family

ID=27265656

Family Applications (1)

Application Number Title Priority Date Filing Date
HK78897A HK78897A (en) 1991-05-16 1997-06-12 Antiviral combinations containing nucleoside analogs

Country Status (25)

Country Link
US (2) US5627186A (sk)
EP (1) EP0513917B2 (sk)
JP (1) JP2868671B2 (sk)
KR (1) KR100246687B1 (sk)
CN (1) CN1045961C (sk)
AT (1) ATE131730T1 (sk)
AU (2) AU1787492A (sk)
CA (1) CA2068790C (sk)
CZ (1) CZ285232B6 (sk)
DE (2) DE19875016I2 (sk)
DK (1) DK0513917T4 (sk)
ES (1) ES2083668T5 (sk)
GR (1) GR3018915T3 (sk)
HK (1) HK78897A (sk)
IE (1) IE73261B1 (sk)
IL (1) IL101883A (sk)
LU (1) LU90234I2 (sk)
MX (1) MX9202279A (sk)
NL (1) NL980018I2 (sk)
NO (2) NO301690B1 (sk)
NZ (2) NZ299240A (sk)
OA (1) OA10058A (sk)
SK (1) SK279262B6 (sk)
TW (1) TW273550B (sk)
WO (1) WO1992020344A1 (sk)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
EP0639971B1 (en) * 1992-05-13 1999-09-22 The Wellcome Foundation Limited Therapeutic combinations
GB9215178D0 (en) * 1992-07-16 1992-08-26 Glaxo Group Ltd Antiviral combinations
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
FR2720397B1 (fr) * 1994-05-24 1996-08-23 Laphal Laboratoires Sa Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
TW401303B (en) * 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
GB9503850D0 (en) * 1995-02-25 1995-04-19 Glaxo Group Ltd Medicaments
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
JP2000515852A (ja) 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
AU9016998A (en) 1997-08-08 1999-03-01 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
PT1045897E (pt) 1998-01-23 2002-07-31 Newbiotics Inc Agentes terapeuticos por catalise enzimatica
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
JP2002518452A (ja) * 1998-06-24 2002-06-25 エモリ ユニバーシティ Ｈｉｖの治療薬物の製造のための他の抗ｈｉｖ薬と組み合わせた３’−アジド−２’，３’−ジデオキシウリジンの使用
WO2001007088A2 (en) 1999-07-22 2001-02-01 Newbiotics, Inc. Methods for treating therapy-resistant tumors
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
EP1567133B1 (en) * 2002-11-08 2007-05-02 Glaxo Group Limited Pharmaceutical antiviral compositions
DK1583542T3 (da) * 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
JP4482883B2 (ja) 2003-05-22 2010-06-16 リードケミカル株式会社 抗ウイルス作用を有する化合物およびその配合剤
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
EP1975923B1 (en) * 2007-03-28 2016-04-27 Nuance Communications, Inc. Multilingual non-native speech recognition
WO2010137027A1 (en) 2009-05-27 2010-12-02 Hetero Research Foundation Solid oral dosage forms of lamivudine
US20130115237A1 (en) 2010-06-09 2013-05-09 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
KR20140138837A (ko) 2012-03-05 2014-12-04 시플라 리미티드 라미부딘, 페스티나비르 및 네비라핀을 포함하는 약학적 항레트로바이러스 조합

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1214611B (it) * 1985-05-22 1990-01-18 Schiena Ricerche Composti per uso cosmetico dermatologico e relative composizioni.
GB8717955D0 (en) * 1987-07-29 1987-09-03 Fujisawa Pharmaceutical Co Prevention & treatment of aids
US5270464A (en) * 1989-03-14 1993-12-14 Janssen Pharmaceutica N.V. Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones
WO1989009056A1 (en) * 1988-03-23 1989-10-05 New York University Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
JPH02504283A (ja) * 1988-03-23 1990-12-06 ニューヨーク　ユニバーシィティ 芳香族多環式ジオン化合物とヌクレオシド類似化合物とを含む抗ウイルス性組成物及びレトロウイルス感染を治療するための方法
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
DE68900926D1 (de) * 1988-09-28 1992-04-09 Sigma Tau Ind Farmaceuti Pharmazeutische zubereitung, die zidovudin und inosiplex oder bestandteile davon enthaelt, fuer die behandlung von aids-verwandten syndromen.
EP0374096B1 (de) * 1988-12-14 1992-12-02 Ciba-Geigy Ag 2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
IL93136A (en) * 1989-02-23 1995-01-24 Janssen Pharmaceutica Nv History of tetrahydroimidazo [1,4] benzodiazepine-2-thione, their preparation and pharmaceutical preparations containing them
GR1000618B (el) * 1989-03-17 1992-08-31 Oncogen Μεθοδος αναστολης hiv χρησιμοποιωντας συνεργιστικους συνδυασμους νουκλεοσιδικων παραγωγων.
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
SE464168B (sv) † 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US5116823A (en) * 1990-02-27 1992-05-26 Roger Williams General Hospital Drug combinations containing AZT
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination

Also Published As

Publication number Publication date
NO1999018I1 (no) 1999-07-22
ATE131730T1 (de) 1996-01-15
DK0513917T3 (da) 1996-02-05
NL980018I2 (nl) 1998-11-02
JP2868671B2 (ja) 1999-03-10
WO1992020344A1 (en) 1992-11-26
CZ285232B6 (cs) 1999-06-16
NZ242754A (en) 1996-11-26
IE921566A1 (en) 1992-11-18
DE69206876D1 (de) 1996-02-01
IE73261B1 (en) 1997-05-21
NL980018I1 (nl) 1998-07-01
US5627186A (en) 1997-05-06
ES2083668T5 (es) 2001-06-16
CA2068790A1 (en) 1992-11-17
AU661307B2 (en) 1995-07-20
CN1068570A (zh) 1993-02-03
NO301690B1 (no) 1997-12-01
CN1045961C (zh) 1999-10-27
DE69206876T3 (de) 2004-08-12
CZ242893A3 (en) 1994-07-13
NZ299240A (en) 2004-11-26
IL101883A0 (en) 1992-12-30
NO921947L (no) 1992-11-17
TW273550B (sk) 1996-04-01
EP0513917A1 (en) 1992-11-19
IL101883A (en) 1998-10-30
SK279262B6 (sk) 1998-08-05
AU1787492A (en) 1992-12-30
ES2083668T3 (es) 1996-04-16
KR920021148A (ko) 1992-12-18
DE19875016I2 (de) 2004-07-01
OA10058A (en) 1996-10-14
NO921947D0 (no) 1992-05-15
EP0513917B2 (en) 2001-03-07
CA2068790C (en) 2005-06-07
SK119993A3 (en) 1994-04-06
JPH06234641A (ja) 1994-08-23
GR3018915T3 (en) 1996-05-31
DK0513917T4 (da) 2001-06-25
DE69206876T2 (de) 1996-05-23
MX9202279A (es) 1992-11-01
LU90234I2 (fr) 1998-06-24
AU1627992A (en) 1992-11-19
US5859021A (en) 1999-01-12
KR100246687B1 (ko) 2000-04-01
EP0513917B1 (en) 1995-12-20

Similar Documents

Publication Publication Date Title
HK78897A (en) Antiviral combinations containing nucleoside analogs
KR0156747B1 (en) Use of 1,3-oxathiolan nucleoside analogues in the treatment of hepatitis-b
GR3026218T3 (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro derivatives of alpha D-neuraminic acid
IL101144A0 (en) Pharmaceutical compositions containing 1,3-oxathiolane nucleoside analogue and derivatives thereof for the treatment of hepatitis b virus infections
GB8822546D0 (en) Antiviral combinations
IL93594A0 (en) Pharmaceutical compositions containing an imidazopyrimidone derivative
ZA898926B (en) Antiviral compounds
DK0728002T3 (da) Anvendelse af 2-aminopurinderivater til behandling og forebyggelse af humant herpesvirus 7-infektioner
DK0728001T3 (da) Anvendelse af 2-aminopurinderivater til behandling og forebyggelse af humant herpesvirus 6-infektioner

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20120510